

Marion Delcroix

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1626450/publications.pdf>

Version: 2024-02-01

183
papers

19,575
citations

31976

53
h-index

11308

136
g-index

185
all docs

185
docs citations

185
times ranked

11513
citing authors

#	ARTICLE	IF	CITATIONS
1	Magnetic resonance relaxometry of the liver - a new imaging biomarker to assess right heart failure in pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 86-94.	0.6	5
2	Residual pulmonary hypertension after pulmonary thromboendarterectomy: incidence, pathogenesis and therapeutic options. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 163-165.	1.7	3
3	Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. <i>European Respiratory Journal</i> , 2022, 59, 2102024.	6.7	57
4	COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 60, 2102311.	6.7	124
5	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. <i>European Heart Journal</i> , 2022, 43, 183-189.	2.2	83
6	Prediction of chronic thromboembolic pulmonary hypertension with standardised evaluation of initial computed tomography pulmonary angiography performed for suspected acute pulmonary embolism. <i>European Radiology</i> , 2022, 32, 2178-2187.	4.5	18
7	Chronic thromboembolic pulmonary hypertension: diagnosis, operability assessment and patient selection for pulmonary endarterectomy. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 82-97.	1.7	9
8	European Respiratory Society statement on long COVID follow-up. <i>European Respiratory Journal</i> , 2022, 60, 2102174.	6.7	81
9	Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 716-721.	0.6	28
10	ERS statement on chronic thromboembolic pulmonary hypertension. <i>Pulmonologiya</i> , 2022, 32, 13-52.	0.8	0
11	Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 971-981.	0.6	9
12	Impaired biventricular contractile reserve in patients with diastolic dysfunction: insights from exercise stress echocardiography. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1042-1052.	1.2	3
13	ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. <i>ERJ Open Research</i> , 2022, 8, 00665-2021.	2.6	2
14	Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. <i>Lancet Respiratory Medicine</i> , 2022, 10, 937-948.	10.7	57
15	Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension. <i>Advances in Therapy</i> , 2022, 39, 4374-4390.	2.9	2
16	Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. <i>European Heart Journal</i> , 2021, 42, 2284-2295.	2.2	51
17	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 178, 106220.	2.9	23
18	Residential air pollution increases the risk for persistent pulmonary hypertension after pulmonary endarterectomy. <i>European Respiratory Journal</i> , 2021, 57, 2002680.	6.7	3

#	ARTICLE	IF	CITATIONS
19	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 177, 106241.	2.9	13
20	Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study. <i>Thorax</i> , 2021, 76, 1002-1009.	5.6	41
21	Oxygen Pathway Limitations in Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2021, 143, 2061-2073.	1.6	19
22	PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 196.	2.7	11
23	Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. <i>ERJ Open Research</i> , 2021, 7, 00850-2020.	2.6	65
24	A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension. <i>ERJ Open Research</i> , 2021, 7, 00719-2020.	2.6	14
25	Pulmonary Hypertension in Patients With COPD. <i>Chest</i> , 2021, 160, 678-689.	0.8	55
26	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1301-1326.	0.6	36
27	Right ventricular and cyclic guanosine monophosphate signalling abnormalities in stages B and C of heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, , .	3.1	4
28	Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 1255-1268.	1.7	8
29	ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2002828.	6.7	287
30	MACITENTAN TREATMENT EFFECT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION TAKING SPIRONOLACTONE: POST-HOC ANALYSIS OF THE PHASE 3 SERAPHIN TRIAL. <i>Chest</i> , 2021, 160, A2284-A2286.	0.8	0
31	Response by Howden et al to Letter Regarding Article, "Oxygen Pathway Limitations in Patients With Chronic Thromboembolic Pulmonary Hypertension". <i>Circulation</i> , 2021, 144, e330-e331.	1.6	0
32	Incremental Experience in In Vitro Primary Culture of Human Pulmonary Arterial Endothelial Cells Harvested from Swan-Ganz Pulmonary Arterial Catheters. <i>Cells</i> , 2021, 10, 3229.	4.1	2
33	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.	2.2	2,426
34	Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 151-161.	3.8	42
35	ERS International Congress, Madrid, 2019: highlights from the Pulmonary Vascular Diseases Assembly. <i>ERJ Open Research</i> , 2020, 6, 00304-2020.	2.6	2
36	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1435-1444.	0.6	104

#	ARTICLE	IF	CITATIONS
37	COVID-19 in lung transplant patients: A case series. American Journal of Transplantation, 2020, 20, 3234-3238.	4.7	37
38	COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. ERJ Open Research, 2020, 6, 00520-2020.	2.6	40
39	Intravascular Leiomyomatosis as a Rare Cause of Nonthrombotic Pulmonary Embolism. Case Reports in Vascular Medicine, 2020, 2020, 1-4.	0.2	1
40	Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration. European Respiratory Journal, 2020, 55, 2001047.	6.7	3
41	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. Journal of Clinical Medicine, 2020, 9, 1456.	2.4	21
42	Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. European Respiratory Journal, 2020, 55, 2000189.	6.7	55
43	Beta 3 adrenoceptor: a potential therapeutic target for pulmonary arterial hypertension. , 2020, , .		0
44	Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial. , 2020, , .		0
45	Risk assessment, therapy and cardiovascular comorbidity in patients with pulmonary arterial hypertension. , 2020, , .		0
46	Balloon Pulmonary Angioplasty for the Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension: Single-Center Experience with Low Initial Complication Rate. Journal of Vascular and Interventional Radiology, 2019, 30, 1265-1272.	0.5	27
47	CCR2/CCR5-mediated macrophage-smooth muscle cell crosstalk in pulmonary hypertension. European Respiratory Journal, 2019, 54, 1802308.	6.7	73
48	Cytokines trigger disruption of endothelium barrier function and p38MAP kinase activation in <i>BMPR2</i> -silenced human lung microvascular endothelial cells. Pulmonary Circulation, 2019, 9, 1-13.	1.7	12
49	Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 177-198.	0.5	13
50	The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801805.	6.7	31
51	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005095.	2.2	8
52	Highlights from the ERS International Congress 2018: Assembly 13 - Pulmonary Vascular Diseases. ERJ Open Research, 2019, 5, 00202-2018.	2.6	0
53	Assembly 13: placing the pulmonary circulation in the heart of ERS. Breathe, 2019, 15, 88-89.	1.3	1
54	Double-lung versus heart-lung transplantation for precapillary pulmonary arterial hypertension: a 24-year single-center retrospective study. Transplant International, 2019, 32, 717-729.	1.6	29

#	ARTICLE	IF	CITATIONS
55	Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661882344.	2.6	17
56	Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. <i>European Respiratory Review</i> , 2019, 28, 190050.	7.1	39
57	Pulmonary endarterectomy in a 12-year-old boy with multiple comorbidities. <i>Pulmonary Circulation</i> , 2019, 9, 1-4.	1.7	9
58	Impaired Cardiac Reserve and Abnormal Vascular Load Limit Exercise Capacity in Chronic Thromboembolic Disease. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1444-1456.	5.3	56
59	TGF β 2 and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension. <i>Drug Discovery Today</i> , 2019, 24, 703-716.	6.4	64
60	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1800332.	6.7	110
61	Serial pulmonary vascular resistance assessment in patients late after ventricular septal defect repair. <i>International Journal of Cardiology</i> , 2019, 282, 38-43.	1.7	3
62	Chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801915.	6.7	607
63	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , 2018, 71, 752-763.	2.8	82
64	Macitentan in pulmonary hypertension due to left ventricular dysfunction. <i>European Respiratory Journal</i> , 2018, 51, 1701886.	6.7	139
65	Postoperative left ventricular function in different types of pulmonary hypertension: a comparative study. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018, 26, 813-819.	1.1	5
66	Low-flow support of the chronic pressure-overloaded right ventricle induces reversed remodeling. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 151-160.	0.6	15
67	Hypocalcemia after Denosumab in a Pulmonary Hypertension Patient Receiving Epoprostenol. <i>Respiration</i> , 2018, 95, 139-142.	2.6	2
68	Key topics in pulmonary vascular diseases (assembly 13) from the European Respiratory Society 2018 Parisian Congress. <i>Journal of Thoracic Disease</i> , 2018, 10, S3029-S3033.	1.4	1
69	Determinants of diagnostic delay in chronic thromboembolic pulmonary hypertension: results from the European CTEPH Registry. <i>European Respiratory Journal</i> , 2018, 52, 1801687.	6.7	78
70	Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. <i>European Respiratory Journal</i> , 2018, 52, 1800248.	6.7	61
71	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. <i>PLoS ONE</i> , 2018, 13, e0193226.	2.5	33
72	Survival in medically treated chronic thromboembolic pulmonary hypertension patients. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
73	Targeting CCR2 and CCR5 to inhibit macrophage/pulmonary artery smooth muscle cells cross-talk in pulmonary hypertension. , 2018, , .		0
74	Activation of the Beta-3 adrenoceptor in experimental pulmonary hypertension. , 2018, , .		0
75	Local inhibition of angiogenesis combined with repeated blood clot embolization induces chronic thromboembolic pulmonary hypertension in rabbits. , 2018, , .		0
76	Effect of BMPRII on endothelial function in human lung microvascular endothelial cells. , 2018, , .		0
77	Pulmonary arterial pressure predicts nocturnal hypoxemia in CTEPH patients.. , 2018, , .		0
78	Right ventricular and pulmonary vascular reserve in asymptomatic BMPR2 mutation carriers. Journal of Heart and Lung Transplantation, 2017, 36, 148-156.	0.6	8
79	Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. European Respiratory Journal, 2017, 49, 1601792.	6.7	339
80	MELODY-1: A PILOT STUDY OF MACITENTAN IN PULMONARY HYPERTENSION DUE TO LEFT VENTRICULAR DYSFUNCTION. Journal of the American College of Cardiology, 2017, 69, 1880.	2.8	3
81	Diagnosis of chronic thromboembolic pulmonary hypertension. European Respiratory Review, 2017, 26, 160108.	7.1	114
82	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respiratory Medicine, the, 2017, 5, 785-794.	10.7	201
83	Single-Center Experience with Intimal Sarcoma, an Ultra-Orphan, Commonly Fatal Mesenchymal Malignancy. Oncology Research and Treatment, 2017, 40, 353-359.	1.2	19
84	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. European Respiratory Journal, 2017, 50, 1700740.	6.7	489
85	Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension. Chest, 2017, 151, 106-118.	0.8	46
86	Systolic and diastolic unloading by mechanical support of the acute vs the chronic pressure overloaded right ventricle. Journal of Heart and Lung Transplantation, 2017, 36, 457-465.	0.6	11
87	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 2017, 38, 1147-1155.	2.2	65
88	Single-center experience with intimal sarcoma, an ultra-orphan, commonly fatal mesenchymal malignancy.. Journal of Clinical Oncology, 2017, 35, e22532-e22532.	1.6	1
89	Pulmonary arterial hypertension-related morbidity is prognostic for survival: insights from the SERAPHIN and GRIPHON studies. , 2017, , .		0
90	Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
91	Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL. , 2017, , .		0
92	Impact of insomnia on exercise capacity and quality of life in patients with pulmonary arterial hypertension. , 2017, , .		0
93	Administration of mitomycin results in pulmonary hypertension and vascular remodeling in rabbits. , 2017, , .		0
94	Extracellular Calpain/Calpastatin Balance Is Involved in the Progression of Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 337-351.	2.9	21
95	Is Right Ventricular Remodeling in Pulmonary Hypertension Dependent on Etiology? An Echocardiographic Study. Echocardiography, 2016, 33, 546-554.	0.9	28
96	Letter by Belge et al Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models" Circulation, 2016, 133, e591.	1.6	4
97	Osteopontin, a Key Mediator Expressed by Senescent Pulmonary Vascular Cells in Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1879-1890.	2.4	46
98	Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension. European Respiratory Journal, 2016, 48, 470-483.	6.7	79
99	Chronic Thromboembolic Pulmonary Hypertension. Epidemiology and Risk Factors. Annals of the American Thoracic Society, 2016, 13, S201-S206.	3.2	101
100	BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators. Pflugers Archiv European Journal of Physiology, 2016, 468, 1969-1983.	2.8	20
101	Apical traction: a novel visual echocardiographic parameter to predict survival in patients with pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2016, 17, 177-183.	1.2	18
102	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2016, 133, 859-871.	1.6	506
103	Accuracy of Echocardiography to Evaluate Pulmonary Vascular and RV Function During Exercise. JACC: Cardiovascular Imaging, 2016, 9, 532-543.	5.3	120
104	Atrial volume and function during exercise in health and disease. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 104.	3.3	25
105	IL18 induces p38 MAP kinase activation and adhesion capacities in BMPRII knocked down human lung microvascular endothelial cells. , 2016, , .		0
106	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. European Respiratory Journal, 2015, 46, 1711-1720.	6.7	39
107	Prediction of hemodynamic improvement after pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension using non-invasive imaging. International Journal of Cardiovascular Imaging, 2015, 31, 143-150.	1.5	16
108	Pulmonary Vascular and Right Ventricular Reserve in Patients With Normalized Resting Hemodynamics After Pulmonary Endarterectomy. Journal of the American Heart Association, 2015, 4, e001602.	3.7	87

#	ARTICLE	IF	CITATIONS
109	Mechanical support of the pressure overloaded right ventricle: an acute feasibility study comparing low and high flow support. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 309, H615-H624.	3.2	14
110	Pulmonary arterial hypertension: the burden of disease and impact on quality of life. <i>European Respiratory Review</i> , 2015, 24, 621-629.	7.1	128
111	Role for Telomerase in Pulmonary Hypertension. <i>Circulation</i> , 2015, 131, 742-755.	1.6	36
112	Exercise pathophysiology and sildenafil effects in chronic thromboembolic pulmonary hypertension. <i>Heart</i> , 2015, 101, 637-644.	2.9	38
113	Clinical significance of dynamic pulmonary vascular resistance in two populations at risk of pulmonary arterial hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 564-570.	1.2	14
114	Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2015, 46, 431-443.	6.7	127
115	Effect of Macitentan on Hospitalizations. <i>JACC: Heart Failure</i> , 2015, 3, 1-8.	4.1	51
116	Is the time constant of the pulmonary circulation truly constant?. <i>European Respiratory Journal</i> , 2014, 43, 1541-1542.	6.7	11
117	CCR5 as a Treatment Target in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 130, 880-891.	1.6	64
118	Response to Letters Regarding Article, "Anticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPETE)" <i>Circulation</i> , 2014, 130, e110-2.	1.6	5
119	Clinical value of echocardiographic Doppler-derived right ventricular dp/dt in patients with pulmonary arterial hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1411-1419.	1.2	25
120	Anticoagulation and Survival in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 129, 57-65.	1.6	317
121	Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension?. <i>European Respiratory Journal</i> , 2014, 44, 842-845.	6.7	4
122	Prediction of outcome after PEA in chronic thromboembolic pulmonary hypertension using indexed pulmonary artery diameter. <i>European Respiratory Journal</i> , 2014, 43, 909-912.	6.7	9
123	Emotional symptoms and quality of life in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 800-808.	0.6	43
124	Interaction between respiration and right versus left ventricular volumes at rest and during exercise: a real-time cardiac magnetic resonance study. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 306, H816-H824.	3.2	64
125	A different view on predictors of pulmonary hypertension in secundum atrial septal defect. <i>International Journal of Cardiology</i> , 2014, 176, 833-840.	1.7	63
126	EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. <i>American Heart Journal</i> , 2014, 167, 210-217.	2.7	59

#	ARTICLE	IF	CITATIONS
127	A Rare Central Thoracic Tumor. <i>Journal of Thoracic Oncology</i> , 2014, 9, 897-899.	1.1	1
128	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 809-818.	27.0	1,168
129	Geometry of the right heart and tricuspid regurgitation to exclude elevated pulmonary artery pressure: New insights. <i>International Journal of Cardiology</i> , 2013, 168, 3866-3871.	1.7	12
130	Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D92-D99.	2.8	503
131	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. <i>International Journal of Cardiology</i> , 2013, 168, 871-880.	1.7	357
132	Bosentan for mild pulmonary vascular disease in Asd patients (the BOMPA trial): a double-blind, randomized controlled, pilot trial. <i>International Journal of Cardiology</i> , 2013, 168, 5081-5082.	1.7	5
133	Predictive model for late atrial arrhythmia after closure of an atrial septal defect. <i>International Journal of Cardiology</i> , 2013, 164, 318-322.	1.7	22
134	Worsening in oxygen saturation and exercise capacity predict adverse outcome in patients with Eisenmenger syndrome. <i>International Journal of Cardiology</i> , 2013, 168, 1386-1392.	1.7	27
135	Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. <i>Nature Genetics</i> , 2013, 45, 518-521.	21.4	93
136	Amorphous Silica Nanoparticles Promote Monocyte Adhesion to Human Endothelial Cells: Size-Dependent Effect. <i>Small</i> , 2013, 9, 430-438.	10.0	36
137	Abnormal Liver Uptake of ^{99m} Tc-Macroaggregated Albumin in a Patient with Superior Vena Cava Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1028-1028.	5.6	5
138	Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2013, 41, 224-232.	6.7	100
139	Chronic post-embolic pulmonary hypertension: a new target for medical therapies?. <i>European Respiratory Review</i> , 2013, 22, 258-264.	7.1	14
140	Right ventricular load and function during exercise in patients with open and closed atrial septal defect type secundum. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 597-604.	1.8	17
141	NF- κ B pathway is involved in CRP-induced effects on pulmonary arterial endothelial cells in chronic thromboembolic pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2013, 305, L934-L942.	2.9	36
142	Measurement of right ventricular pressure by telemetry in conscious moving rabbits. <i>Laboratory Animals</i> , 2013, 47, 184-193.	1.0	7
143	Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy. <i>Chest</i> , 2013, 144, 876A.	0.8	3
144	Do parameters of cardiac function predict long-term outcomes in patients with pulmonary arterial hypertension? Data from SERAPHIN, a randomized controlled study of macitentan. <i>Chest</i> , 2013, 144, 870B.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan. <i>Chest</i> , 2013, 144, 879A.	0.8	1
146	Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. <i>Thrombosis and Haemostasis</i> , 2013, 110, 83-91.	3.4	96
147	Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2012, 40, 886-894.	6.7	74
148	Characterization of proximal pulmonary arterial cells from chronic thromboembolic pulmonary hypertension patients. <i>Respiratory Research</i> , 2012, 13, 27.	3.6	41
149	Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2012, 40, 874-880.	6.7	267
150	Right Ventricular Function in Patients With Eisenmenger Syndrome. <i>American Journal of Cardiology</i> , 2012, 109, 1206-1211.	1.6	27
151	The importance of pulmonary artery pressures on late atrial arrhythmia in transcatheter and surgically closed ASD type secundum. <i>International Journal of Cardiology</i> , 2011, 152, 192-195.	1.7	27
152	Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registry. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 141, 702-710.	0.8	605
153	The outcome of Eisenmenger patients with trisomy 21 does not differ from patients without trisomy 21. <i>Acta Cardiologica</i> , 2011, 66, 293-301.	0.9	7
154	Cardiopulmonary Exercise Testing and SF-36 in Patients With Atrial Septal Defect Type Secundum. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2011, 31, 308-315.	2.1	18
155	Should We Focus on Hematocrit or Hemoglobin in Patients With Eisenmenger Syndrome?. <i>American Journal of Cardiology</i> , 2011, 108, 899-902.	1.6	0
156	Regional right ventricular deformation in patients with open and closed atrial septal defect. <i>European Journal of Echocardiography</i> , 2011, 12, 206-213.	2.3	39
157	Chronic Thromboembolic Pulmonary Hypertension (CTEPH). <i>Circulation</i> , 2011, 124, 1973-1981.	1.6	860
158	Iron deficiency is associated with adverse outcome in Eisenmenger patients. <i>European Heart Journal</i> , 2011, 32, 2790-2799.	2.2	76
159	Pulmonary Vascular Resistance as Assessed by Bicycle Stress Echocardiography in Patients With Atrial Septal Defect Type Secundum. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 237-245.	2.6	37
160	Optimising the management of pulmonary arterial hypertension patients: emergency treatments. <i>European Respiratory Review</i> , 2010, 19, 204-211.	7.1	60
161	Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy. <i>European Respiratory Review</i> , 2009, 18, 253-259.	7.1	18
162	A modified technique of stent fenestration of the interatrial septum improves patients with pulmonary hypertension. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 173-179.	1.7	29

#	ARTICLE	IF	CITATIONS
163	C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1211-1218.	2.8	220
164	End Points and Clinical Trial Design in Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S97-S107.	2.8	209
165	Updated Clinical Classification of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S43-S54.	2.8	1,919
166	The Belgian Eisenmenger syndrome registry: Implications for treatment strategies?. <i>Acta Cardiologica</i> , 2009, 64, 447-453.	0.9	41
167	Time course of reversed cardiac remodeling after pulmonary endarterectomy in patients with chronic pulmonary thromboembolism. <i>European Radiology</i> , 2008, 18, 792-799.	4.5	50
168	Congenital veno-venous malformations of the liver: Widely variable clinical presentations. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, e390-4.	2.8	84
169	Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2127-2134.	2.8	506
170	Tracheotomy: clinical review and guidelines. <i>European Journal of Cardio-thoracic Surgery</i> , 2007, 32, 412-421.	1.4	292
171	Regional Right Ventricular Dysfunction in Chronic Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2007, 20, 1172-1180.	2.8	117
172	Effect of adenovirus-mediated gene transfer of nitric oxide synthase on vascular reactivity of rat isolated pulmonary arteries. <i>Pflugers Archiv European Journal of Physiology</i> , 2006, 452, 213-221.	2.8	6
173	Advanced therapy may delay the need for transplantation in patients with the Eisenmenger syndrome. <i>European Heart Journal</i> , 2006, 27, 1472-1477.	2.2	44
174	Anaesthesia management for pulmonary endarterectomy. <i>Current Opinion in Anaesthesiology</i> , 2005, 18, 63-76.	2.0	7
175	Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. <i>Perfusion (United Kingdom)</i> , 2005, 20, 101-108.	1.0	20
176	The Evaluation of Pulmonary Hypertension Using Right Ventricular Myocardial Isovolumic Relaxation Time. <i>Journal of the American Society of Echocardiography</i> , 2005, 18, 1113-1120.	2.8	42
177	Prostanoid therapy for pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S56-S61.	2.8	184
178	Differential changes in regional right ventricular function before and after a bilateral lung transplantation: an ultrasonic strain and strain rate study. <i>Journal of the American Society of Echocardiography</i> , 2003, 16, 432-436.	2.8	30
179	The use of ECG and respiratory triggering to improve the sensitivity of oxygen-enhanced proton MRI of lung ventilation. <i>European Radiology</i> , 2003, 13, 1260-1265.	4.5	29
180	Inhaled Iloprost for Severe Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 2002, 347, 322-329.	27.0	1,626

#	ARTICLE	IF	CITATIONS
181	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Journal of the American College of Cardiology, 2002, 39, 1496-1502.	2.8	584
182	COMBINED LIVER AND (HEART-)LUNG TRANSPLANTATION IN LIVER TRANSPLANT CANDIDATES WITH REFRACTORY PORTOPULMONARY HYPERTENSION. Transplantation, 2002, 73, 140-156.	1.0	40
183	Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: A cohort study in Belgium. European Respiratory Journal, 0, , 2102335.	6.7	0